We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
previous     next      view all

08.07.14   #AskDrDurie: Is it okay to take vitamin B12 on the same day as Velcade?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a myeloma patient’s question about taking a supplement like vitamin B12 on the same day as Velcade.


07.30.14   #AskDrDurie: What are the important aspects of different types of imaging, such as regular x-rays, MRI, CT, and PET?
In this week's #AskDrDurie episode, Dr. Brian Durie of the IMF explains the difference between x-rays, MRI, CT, and PET image scans. Each one has its place in detecting myeloma, and he walks viewers through each.

07.23.14   #AskDrDurie: Should I have an ASCT if I've been through therapy and am in remission?

In this week's #AskDrDurie, IMF Chairman and Co-Founder, Dr. Brian Durie answers a patient's inquiry about the benefits and necessity of having an autologous stem cell transplant (ASCT) if treatment for myeloma has already been completed, with remission as the result.


07.16.14   #AskDrDurie: How can myeloma suddenly go from standard to high risk?
In this episode of #AskDrDurie, IMF Co-Founder and Chairman Dr. Brian G.M. Durie answers a patient submitted question regarding receiving an initial diagnosis of standard myeloma, having treatment, and then being told the myeloma was high risk. He explains when and why that can happen and discusses different kinds of testing involved.

07.09.14   #AskDrDurie: Can a low white blood cell count be enough to trigger a need for myeloma therapy?

In this episode of #AskDrDurie, IMF Chairman and Co-Founder Dr. Brian G.M. Durie talks about what a low white blood cell count means when it comes to myeloma.


07.02.14   #AskDrDurie: Does age make a difference in selecting myeloma treatment?

In this episode of #AskDrDurie, IMF Chairman and Co-Founder Dr. Brian G.M. Durie discusses the important factors one must consider when selecting individualized treatment for myeloma.


06.25.14   #AskDrDurie: Is MRI testing important to see if treatment is necessary for smoldering myeloma?

In this episode of #AskDrDurie, Dr. Brian Durie discusses the importance of MRI testing, specifically when it comes to patients with smoldering myeloma.


06.18.14   #AskDrDurie: Are there maintenance therapy recommendations for myeloma patients with t(4;14)?

In this episode of #AskDrDurie, IMF Chairman and Co-Founder Dr. Brian G.M. Durie addresses a question about what kind of maintenance therapy is recommended for those myeloma patients who have the t(4;14) chromosome abnormality.


06.12.14   #AskDrDurie: Are clinical trials part of the Black Swan Research Initiative(R), and if so, how can I participate?

In this episode of #AskDrDurie, Dr. Brian Durie, IMF Chairman and Co-Founder, talks about the Black Swan Research Initiative(R)'s various clinical trials and how eligible patients can get more information and potentially participate in them.


06.04.14   #AskDrDurie: How does the new flow cytometry testing for MRD compare to molecular testing?

In this episode of #AskDrDurie, Dr. Brian G.M. Durie, IMF Chairman and Co-Founder, discusses the sensitivity and accessibility of the flow cytometry method of MRD testing. 


previous     next      view all